Target intelligence / Profile preview

Inhibin alpha chain (INHA)

Target
INHA
Molecular classification
Hormone, Growth/differentiation factor, TGF-beta superfamily member, Protein/glycoprotein
01

Overview

Inhibin alpha chain is a glycoprotein subunit that pairs with beta subunits to form the biologically active hormone inhibin (inhibin A and inhibin B). Inhibin functions to inhibit FSH secretion from the anterior pituitary and thereby plays a crucial role in reproductive endocrine regulation. It belongs to the TGF-beta superfamily. Inhibin is produced primarily by gonadal tissues (granulosa cells in ovaries, Sertoli cells in testes), but expression also occurs in extragonadal tissues. Inhibin acts as a tumor suppressor, with abnormal levels serving as biomarkers in various cancers, especially ovarian granulosa-cell tumors. It is not directly targeted by current drugs, but its levels are clinically monitored to inform therapy and disease outcomes. Mechanistically, inhibin blocks activin signaling via engagement with activin receptors and the coreceptor betaglycan.

Other names
Inhibin alphaalpha inhibinINHAinhibin alpha subunitinhibin A alpha subunit
02

Mechanism of action

Drugs targeting this molecule would likely act via antagonism or modulation of inhibin's inhibitory effect on FSH secretion or by impacting its tumor suppressor activity. Inhibin's mechanism involves antagonizing activin actions by binding to activin receptors, aided by coreceptors such as betaglycan.

03

Biological functions

Inhibition of follicle-stimulating hormone (FSH) secretion (pituitary)Regulation of gonadal stromal cell proliferationTumor suppressionNegative feedback in reproductive endocrinologyGrowth/differentiation signaling
04

Disease associations

Cancer (notably ovarian granulosa-cell tumors; also prostate cancer expression is associated with tumor progression)Endocrine/reproductive disordersBiomarker in granulosa-cell tumors
05

Safety considerations

Therapeutic modulation of inhibin alpha may disrupt hormonal balance (FSH, LH), affecting fertility and secondary sexual characteristicsOff-target effects in cancer/benign neoplasmsLimited knowledge of systemic safety profile due to the lack of direct agentsInhibin alpha expression varies widely in tissues, introducing complexity for targeted therapy
06

Interacting drugs

No widely approved drugs that directly target inhibin alpha.
07

Biomarkers

Serum inhibin levels (notably inhibin A or B, used for diagnosis and monitoring of granulosa-cell tumors and reproductive function)

Beyond the preview

Go deeper on Inhibin alpha chain (INHA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibin alpha chain (INHA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call